Evidence map›Paper›PMID 38170301›Full record

Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2024

Patterns and influencing factors of exercise attendance of breast cancer patients during neoadjuvant chemotherapy.

Siri Goldschmidt, Martina E Schmidt, Friederike Rosenberger, Joachim Wiskemann, Karen Steindorf

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02999074 (A Randomized 3-arm Exercise Intervention Trial for Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02999074 naactive not recruitingnot on this map

A Randomized 3-arm Exercise Intervention Trial for Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

TypeinterventionalSponsorGerman Cancer Research CenterRan2016 to 2025Enrolled183ConditionsBreast CancerArmsResistance exercise, Aerobic exercise, Usual care during neoadjuvant chemotherapy/Exercise after surgery
3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Siri GoldschmidtDivision of Physical Activity, Prevention and Cancer, German Cancer Research Center (DKFZ), and National Center for Tumor Diseases (NCT), Heidelberg, a partnership between DKFZ and University Medical Center, Heidelberg, Germany.
Martina E SchmidtDivision of Physical Activity, Prevention and Cancer, German Cancer Research Center (DKFZ), and National Center for Tumor Diseases (NCT), Heidelberg, a partnership between DKFZ and University Medical Center, Heidelberg, Germany.
Friederike RosenbergerDepartment of Medical Oncology, University Medical Center, and National Center for Tumor Diseases (NCT), Heidelberg, a partnership between DKFZ and University Medical Center, Heidelberg, Germany.
Joachim WiskemannDepartment of Medical Oncology, University Medical Center, and National Center for Tumor Diseases (NCT), Heidelberg, a partnership between DKFZ and University Medical Center, Heidelberg, Germany.
Karen SteindorfDivision of Physical Activity, Prevention and Cancer, German Cancer Research Center (DKFZ), and National Center for Tumor Diseases (NCT), Heidelberg, a partnership between DKFZ and University Medical Center, Heidelberg, Germany. k.steindorf@dkfz.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPerforming 2-3 exercise sessions/week may relieve therapy-related side effects of breast cancer patients (BRCA) and improve their quality of life. However, attendance to the exercise sessions is often impaired. Thus, we investigated patterns and possible influencing factors of attendance to an aerobic (AT) or resistance training (RT) intervention in BRCA during neoadjuvant chemotherapy.

methodsBRCA (N = 122) were randomly allocated to supervised AT or RT twice weekly during neoadjuvant chemotherapy (18 ± 4 weeks). Attendance was calculated individually and group-wise per training week as the percentage of the performed sessions out of the prescribed sessions. Possible influencing factors were investigated using multiple regression analyses.

resultsMean individual attendance was 44.1% ± 29.3% with no significant differences between the groups. Group-wise attendance was highest in the first 6 weeks of training with ≥ 60% for AT and ≥ 50% for RT, but decreased over the course of the intervention accompanying chemotherapy. Significantly higher attendance was associated with not having vs. having nausea (ß =  - 14.57; p = 0.007) and not having vs. having pain (ß =  - 12.07; p = 0.12), whereas fatigue did not show any association (ß =  - 0.006; p = 0.96). Having been randomized into a preferred intervention group (48.8%) showed no association with attendance. Yet, patients' rating of the exercise intervention as "good"/ "very good" (58.7%) was significantly associated with higher attendance (p = 0.01).

conclusionFor both exercise interventions, group-wise attendance/training week decreased during chemotherapy despite good intervention ratings. While some patients never started, others trained almost constantly twice weekly. The study revealed that patients who are nauseous or experience pain may need more support to attend more exercise sessions. Trial Registration Clinicaltrials.gov: NCT02999074 from May 6, 2016.

Indexed as

Breast NeoplasmsExerciseExercise TherapyFemaleHumansNeoadjuvant TherapyPainQuality of LifeAttendanceBreast neoplasmsExercise interventionNeoadjuvant chemotherapy

Identifiers

PMID38170301
PMCPMC10764381

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.